Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months…
Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business developmentMARLBOROUGH, Mass.…
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)…
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2…
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression…
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing…
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone…
Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiariesMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April…